Controversies of the hormonal conservative treatment of endometrial cancer

Lucas Minig, Dorella Franchi, Javier Valero De Bernabé, Mario Sideri

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Hysterectomy plus salpingo-oophorectomy represents the standard treatment for patients with well-differentiated endometrial cancer (EC) limited to the endometrium. It is estimated that over 5% of EC are diagnosed in nulliparous women aged 35-44 years. In addition, EC can affect obese women with diabetes, hypertension and other comorbidities increasing the surgical risk. Methods: This article reviews the English literature in PubMed regarding hormonal treatment of EC. Results: Use of hormonal therapies has resulted in complete remission in 60-70%; many of these women were able to achieve full-term pregnancies, and in case of contraindication to surgery, resection could be avoided. Several topics, however, such as patient selection, interobserver histologic evaluation, the type/duration of hormonal treatment, modality of evaluation before treatment and surveillance after treatment, which are still subject to controversy, are therefore discussed in this paper. Conclusion: Uterus-sparing treatment of well-differentiated EC limited to the endometrium is feasible and has acceptable efficacy in women with increased surgical risk or those who wish to preserve their fertility. Although the methods applied to determine disease extent beyond the endometrium are still unsatisfactory, patient selection is a crucial factor determining the outcome of treatment. However, women must be fully informed about the possibility of treatment failure and the necessity of a close follow-up after therapy.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalGynecologic and Obstetric Investigation
Volume75
Issue number3
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Endometrial Neoplasms
Endometrium
Therapeutics
Patient Selection
Conservative Treatment
Ovariectomy
Treatment Failure
Hysterectomy
PubMed
Uterus
Fertility
Comorbidity
Hypertension
Pregnancy

Keywords

  • Fertility sparing
  • High surgical risk
  • Hysteroscopy
  • Levonorgestrel intrauterine device
  • Medroxyprogesterone acetate
  • Megestrol acetate
  • Tumor resection
  • Well-differentiated endometrial carcinoma
  • Young patients

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Controversies of the hormonal conservative treatment of endometrial cancer. / Minig, Lucas; Franchi, Dorella; Valero De Bernabé, Javier; Sideri, Mario.

In: Gynecologic and Obstetric Investigation, Vol. 75, No. 3, 04.2013, p. 145-151.

Research output: Contribution to journalArticle

Minig, Lucas ; Franchi, Dorella ; Valero De Bernabé, Javier ; Sideri, Mario. / Controversies of the hormonal conservative treatment of endometrial cancer. In: Gynecologic and Obstetric Investigation. 2013 ; Vol. 75, No. 3. pp. 145-151.
@article{c5918f467b3449d5816323a4784ec886,
title = "Controversies of the hormonal conservative treatment of endometrial cancer",
abstract = "Background: Hysterectomy plus salpingo-oophorectomy represents the standard treatment for patients with well-differentiated endometrial cancer (EC) limited to the endometrium. It is estimated that over 5{\%} of EC are diagnosed in nulliparous women aged 35-44 years. In addition, EC can affect obese women with diabetes, hypertension and other comorbidities increasing the surgical risk. Methods: This article reviews the English literature in PubMed regarding hormonal treatment of EC. Results: Use of hormonal therapies has resulted in complete remission in 60-70{\%}; many of these women were able to achieve full-term pregnancies, and in case of contraindication to surgery, resection could be avoided. Several topics, however, such as patient selection, interobserver histologic evaluation, the type/duration of hormonal treatment, modality of evaluation before treatment and surveillance after treatment, which are still subject to controversy, are therefore discussed in this paper. Conclusion: Uterus-sparing treatment of well-differentiated EC limited to the endometrium is feasible and has acceptable efficacy in women with increased surgical risk or those who wish to preserve their fertility. Although the methods applied to determine disease extent beyond the endometrium are still unsatisfactory, patient selection is a crucial factor determining the outcome of treatment. However, women must be fully informed about the possibility of treatment failure and the necessity of a close follow-up after therapy.",
keywords = "Fertility sparing, High surgical risk, Hysteroscopy, Levonorgestrel intrauterine device, Medroxyprogesterone acetate, Megestrol acetate, Tumor resection, Well-differentiated endometrial carcinoma, Young patients",
author = "Lucas Minig and Dorella Franchi and {Valero De Bernab{\'e}}, Javier and Mario Sideri",
year = "2013",
month = "4",
doi = "10.1159/000349891",
language = "English",
volume = "75",
pages = "145--151",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Controversies of the hormonal conservative treatment of endometrial cancer

AU - Minig, Lucas

AU - Franchi, Dorella

AU - Valero De Bernabé, Javier

AU - Sideri, Mario

PY - 2013/4

Y1 - 2013/4

N2 - Background: Hysterectomy plus salpingo-oophorectomy represents the standard treatment for patients with well-differentiated endometrial cancer (EC) limited to the endometrium. It is estimated that over 5% of EC are diagnosed in nulliparous women aged 35-44 years. In addition, EC can affect obese women with diabetes, hypertension and other comorbidities increasing the surgical risk. Methods: This article reviews the English literature in PubMed regarding hormonal treatment of EC. Results: Use of hormonal therapies has resulted in complete remission in 60-70%; many of these women were able to achieve full-term pregnancies, and in case of contraindication to surgery, resection could be avoided. Several topics, however, such as patient selection, interobserver histologic evaluation, the type/duration of hormonal treatment, modality of evaluation before treatment and surveillance after treatment, which are still subject to controversy, are therefore discussed in this paper. Conclusion: Uterus-sparing treatment of well-differentiated EC limited to the endometrium is feasible and has acceptable efficacy in women with increased surgical risk or those who wish to preserve their fertility. Although the methods applied to determine disease extent beyond the endometrium are still unsatisfactory, patient selection is a crucial factor determining the outcome of treatment. However, women must be fully informed about the possibility of treatment failure and the necessity of a close follow-up after therapy.

AB - Background: Hysterectomy plus salpingo-oophorectomy represents the standard treatment for patients with well-differentiated endometrial cancer (EC) limited to the endometrium. It is estimated that over 5% of EC are diagnosed in nulliparous women aged 35-44 years. In addition, EC can affect obese women with diabetes, hypertension and other comorbidities increasing the surgical risk. Methods: This article reviews the English literature in PubMed regarding hormonal treatment of EC. Results: Use of hormonal therapies has resulted in complete remission in 60-70%; many of these women were able to achieve full-term pregnancies, and in case of contraindication to surgery, resection could be avoided. Several topics, however, such as patient selection, interobserver histologic evaluation, the type/duration of hormonal treatment, modality of evaluation before treatment and surveillance after treatment, which are still subject to controversy, are therefore discussed in this paper. Conclusion: Uterus-sparing treatment of well-differentiated EC limited to the endometrium is feasible and has acceptable efficacy in women with increased surgical risk or those who wish to preserve their fertility. Although the methods applied to determine disease extent beyond the endometrium are still unsatisfactory, patient selection is a crucial factor determining the outcome of treatment. However, women must be fully informed about the possibility of treatment failure and the necessity of a close follow-up after therapy.

KW - Fertility sparing

KW - High surgical risk

KW - Hysteroscopy

KW - Levonorgestrel intrauterine device

KW - Medroxyprogesterone acetate

KW - Megestrol acetate

KW - Tumor resection

KW - Well-differentiated endometrial carcinoma

KW - Young patients

UR - http://www.scopus.com/inward/record.url?scp=84875646710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875646710&partnerID=8YFLogxK

U2 - 10.1159/000349891

DO - 10.1159/000349891

M3 - Article

C2 - 23548769

AN - SCOPUS:84875646710

VL - 75

SP - 145

EP - 151

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 3

ER -